Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Phase 1/2 Unknown

15 enrolled

Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

NCT05990231 2023-09-11

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Phase 2 Unknown

35 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma

NCT04631731 2023-06-01

ICEMELT

Phase 1/2 Unknown

200 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Stomach Neoplasms, Endometrial Neoplasms

NCT05235438 2023-05-24

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Phase 1 Unknown

16 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT03356782 2020-06-11

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Phase 1/2 Unknown

20 enrolled

Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Bone Neoplasms, Sarcoma, Sarcoma, Ewing

NCT03182803 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03182816 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03179007 2017-06-07

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

Clinical Trials

ENZYMELA

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

ICEMELT

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor